Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech has extended the funding of its cancer therapeutic development collaboration with Curis, agreeing to provide an additional $2 million to support resources dedicated to developing a solid tumor cancers treatment.
Subscribe to our email newsletter
In June 2003, Curis established a collaboration with Genentech for the development of a set of technologies based on inhibition of the Hedgehog signaling pathway, including small molecule Hedgehog pathway inhibitors.
Genentech’s support of Curis personnel and other third-party resources dedicated to the collaboration was due to terminate in June 2005. The amended agreement provides for a six-month extension of support for Curis personnel with an option for an additional six-month extension.
Curis has successfully used its technology and product development approach to produce several promising drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. These drug candidates have resulted from collaborations with several major industry players including Johnson and Johnson and Wyeth, as well as Genentech.